Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 5/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553831 | 0.82 | KLKB1 (0.53) | ALKBH2HPGDSKLKB1ALKBH1EGLN1 | |
| SCHEMBL947911 | 0.73 | CREBBP (0.55) | ALKBH2HPGDSKLKB1ALKBH1EGLN1 | |
| SCHEMBL15155186 | 0.73 | ALKBH2 (0.50) | ALKBH2HPGDSALKBH1EGLN1LDHA | |
| SCHEMBL1414655 | 0.73 | ALKBH2 (0.50) | ALKBH2HPGDSKLKB1ALKBH1EGLN1 | |
| SCHEMBL12913216 | 0.73 | CREBBP (0.55) | ALKBH2HPGDSKLKB1ALKBH1EGLN1 | |
| SCHEMBL949676 | 0.73 | CREBBP (0.55) | ALKBH2HPGDSKLKB1ALKBH1EGLN1 | |
| SCHEMBL27860711 | 0.69 | ALKBH2 (0.45) | ALKBH2HPGDSALKBH1EGLN1LDHA | |
| SCHEMBL25911754 | 0.68 | ITK (0.46) | KLKB1ALKBH1ITK | |
| SCHEMBL31352267 | 0.67 | ACHE (0.44) | ALKBH2HPGDSEGLN1L3MBTL1 | |
| SCHEMBL31075206 | 0.67 | EGLN1 (0.43) | ALKBH2HPGDSKLKB1ALKBH1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-27 | — | — | US | disclosed |
| CN-118613483-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| WO-2023146809-A9 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | ALKBH2 4786/4885HPGDS 402/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.